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INTRODUCTION:Originally described in1838byMuller, phyllodes tumor is a rareﬁbroepithelial neoplasm
which represents roughly 0.3–0.9% of all breast cancers. Phyllodes tumor are divided into benign, border-
line and malignant histologic categories. Malignant phyllodes tumor represent anywhere from 10–30%
of all phyllodes tumors. This group has both the potential to recur locally and metastasize, however not
all malignant phyllodes behave this way. The challenge lays in predicting which tumor will recur locally
or metastasize. Distinguishing this subset of malignant phyllodes tumor is paramount.
PRESENTATION OF CASE: We present a case of malignant phyllodes which presented with metastatic
disease.What is fascinating about this case is not only the initial presentation but also the aggressiveness
of this variation of phyllodes tumor. The patient initially presentedwith a largemasswhich encompassed
herwhole right breast. On surgical pathology themassmeasured roughly 31 cm in diameter andweighed
over 10kg. Within 5 weeks from surgery the patient had suffered brain metastases and also 6 local
recurrent tumors. The patient passed roughly 11 weeks after her ﬁrst visit to our ofﬁce.
CONCLUSION: Despite biopsy proven malignant phyllodes tumor, it was near impossible to predict such
a rapid course of disease progression in our patient. Our case illustrates the unpredictable nature of
this disease in general and it possibly sheds light on a variant of the disease which had undergone an
aggressive transformation.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Originally described in 1838 by Muller, phyllodes tumor is a
rare ﬁbroepithelial neoplasm. This represents roughly 0.3–0.9% of
all breast cancer in women [1,2]. Characterized by a combination
of hyper cellular stroma and cleft-like spaces lined by epithelium,
phyllodes tumor was classically known as cystosarcoma phyllodes
because of the leaf-likeprojections [3,4]. Renamedphyllodes tumor
in the early 1980s, these tumors vary greatly in size and the histo-
logical characteristics continue to be the basis for diagnosis and
sub classiﬁcation. Based on established histological criteria PT are
classiﬁed into three categories – benign, borderline and malignant
[5]. The majority of phyllodes tumors are benign and the primary
concern after surgical treatment is primarily of local recurrence vs.
distant recurrence (Fig. 1a ).
Malignant phyllodes represent anywhere from 10–30% of all
phyllodes tumors [6]. There is an abundance of literature regarding
invasive ductal carcinoma of the breast and its malignant potential
however not asmuch research has been done on phyllodes tumors.
The challenge lays in predicting which tumor will recur locally or
metastasize. Phyllodes tumors which fall into histologically benign
or borderline category essentially never recur [7]. Phyllodes tumors
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which fall into a malignant histological category do have a recur-
rence potential and a metastatic potential on the other hand not
all malignant phyllodes tumors recur or metastasize. Distinguish-
ing this subset of malignant phyllodes tumors is paramount. We
present a case ofmalignant phyllodes tumorwhich presentedwith
metastatic disease, however, what was fascinating about this case
was not the asmuch the initial presentation but the aggressiveness
of this variation of phyllodes tumor (Fig. 1b).
2. Case report
A 50 year-old woman G3P3 presented with a right breast mass
which had been there for ‘several years’. A thorough history and
physical exam revealed a mass localized to the right breast, which
encompassed the entire breast. The mass had increased in size
rapidly in the past 6 weeks and it was painful with multiple open
wounds. Thepatient deniedother lumpsormass,muscle/bonepain
or headaches but complained of fatigue, night sweats and weight
change. There was no signiﬁcant past medical or surgical history or
family history (Fig. 1c).
The physical exam, revealed a ‘melon-sized’ mass throughout
entire right breast. There were multiple ulcerations and many
engorged veins could be seen throughout breast mass as well. The
mass was nodular, hard and was not ﬁxed to the chest wall. There
was no lymphadenopathy found (Fig. 2).
http://dx.doi.org/10.1016/j.ijscr.2014.12.041
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Fig. 1. Right mastectomy specimen.
A core needle biopsy was performed in ofﬁce that day. The
biopsy resultswere found tobeamalignantneoplasmwith carcino-
matous and sarcomatous elements. The cells showed focal marked
pleomorphism with >10 mitoses/10HPF. Focal necrosis was seen.
Thebiopsywasestrogen receptornegative andprogesterone recep-
tor positive. HER2 was also negative (Fig. 3).
A metastatic workup was performed; this included a CT chest,
abdomen, pelvis and also PET scan. The CT of chest was positive
for bilateral chest masses which were concerning for metastatic
disease as well as a 30 cm mass in the right breast. The patient
underwent a right simple mastectomy due to the massive size and
ulcerations of the breast. The right breast mass weighed 10.3 kg at
the time of excision.
The ﬁnal pathology from surgery revealed a malignant phyl-
lodes tumor 31.5 cm length×15.6 cm height. The tumor showed
briskmitotic activity, necrosis, and stromal overgrowth. 1mmclear
margins were attained. A minority of tumor cells in a high grade
portion of round cells in the tumor are cytokeratin positive. A small
portion had the appearance of myxoid sarcoma. Most of the round
cell component is cytokeratin negative; however the positive cells
may represent a true differentiation to an epithelial component
(carcinosarcoma).
In the immediate post-operative period the patient recovered
well. However, within 3weeks of themastectomy the patient com-
plained of headaches and was found to have a right parietal mass.
The patient underwent a right craniotomywhichwas positive for a
right parietal tumor – metastatic malignant phyllodes tumor. Fol-
low up in our breast clinic one week after was unremarkable and
follow up for lung masses was starting. The patient was in clinic
roughly 7 weeks from her original presentation with complaints of
multiple ‘new’ lumps on right post-mastectomy site. Physical exam
revealed 6 newmasseswere found, the largestmeasuring 6 cm and
a mass was palpated in the right axilla. A ﬁne needle aspiration
was performed. These cells where enlarged pleomorphic, epithe-
lioid cells – identical to original tumor. Before any therapies could
be initiated the patient passed shortly after.
3. Discussion
As stated prior, one of the challenges facing physicians for
patients with phyllodes tumor is predicting which patients will
develop local recurrence, metastatic disease or both. The majority
of phyllodes tumors present as ﬁrm, smooth, well-circumscribed,
and rarely painful masses [8]. Most phyllodes tumors occur in
women between ages of 35 and 55 years old [9]. Primary treatment
for phyllodes tumor is surgical. Depending on the size of the tumor;
wide local excision is the treatment of choice. If margins of 1 cm
cannot be attained then simplemastectomy is the next best option.
Most current studies show that wide local excision with adequate
margins yield equivalent results to mastectomy is terms of overall
surviva [10,11]. In general, borderline tumors metastasize, how-
ever this is not common. In a case review by Moffat et al. only
4% of patients with borderline tumors developed metastatic dis-
ease [12]. Malignant tumors develop metastases more commonly.
In some studies metastatic disease has been reported between 9
and 32% [13–15]. Limited research and data is available regarding
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Fig. 2. The tumor shows minimal typical ductal features of phyllodes tumor (see photomicrograph, top panel), a minority of the remainder low-grade malignant (see other
photomicrograph, left half) and majority high-grade malignant ‘overgrown stroma’. Mature squamous ‘pearls’ (see photomicrograph, lower panel) and chondroid areas (see
photomicrograph, middle panel) are obvious divergent differentiation. Foci of geographic necrosis, and broad zones of undifferentiated sarcoma with marked atypia (see
other photomicrograph, right half), tumor giant cells, and numerous mitoses and karyorrhectic cells, constitute the most malignant-appearing areas.
patients like ours; thosewhich presentwithmetastatic disease and
very aggressive tumors as far as treatment after primary surgical
resection. The overall metastatic rate of phyllodes tumor in general
has been reported at <5% [16].
The histological classiﬁcation adopted by the World Health
Organization in the early 1980s allowed pathologist to classify
phyllodes tumor into benign, borderline, and malignant categories
[17,18]. This classiﬁcation is currently the best method at trying
to predict the likelihood of developing local recurrence, metastatic
disease or both. The system does have its limitations; not all malig-
nant tumors recur or metastasize and some borderline tumors do.
Traditionally predictors of malignant behavior include tumor size,
cytological atypia, mitotic rate [19,20], and stromal overgrowth.
Various studies have reported the local recurrence rate at roughly
20% regardless of histological classiﬁcation [21,22]. Some studies
report recurrence rates ofmalignant phyllodes in a range of 20–65%
[23,24]. Some of the factors which have shown an increase in the
change of local recurrence (LR) are tumor size, positive surgical
margins, stromal overgrowth, high mitotic count, and necrosis.
From Oktar et al., stromal overgrowth increased the probability
of LR by 7-fold whereas surgical margin of <1 cm, the risk was
increased by 5-fold and if the tumor size was >10 cm, then the
prevalence of LR was 4x greater than smaller tumors [25]. Of note,
the mean time of LR in their study was 26 months. Similar reports
have also shown a mean time of LR of around 2 years [26]. In the
previously sited report theyhadonepatientwhichpresentedwitha
30 cm tumor who within 2 months of a radical mastectomy devel-
oped a 2 cm chest wall recurrence, which was excised. 2 months
later thispatientpresentedwithmetastaticdiseaseof thecontralat-
eral breast which was found to invade the chest wall and sternum.
Themasswas found tobe inoperable and thepatient diedof thedis-
ease. Geisler et al. had 3 patients which presented with metastatic
disease, one patient had low-grade tumor with metastatic disease
to the lung and thoracic vertebrae who died 14 months after pre-
sentation. Theother2patientspresentedwithhigh-gradeMPTwith
metastatic disease – theﬁrst died37months followingmastectomy
with metastatic disease to the brain and the second patient was
treated with partial mastectomy and died one month later with
metastasis to the right sacral wing [27].
Our patient had all the common factors for high probability of
LR. With a tumor size of >30 cm, surgical margins of <1mm, high
mitotic rate of >10, focal tumor necrosis, marked pleomorphism,
and stromal overgrowth. However, we do not think we could have
predicted such a rapid course. Our patient and a few of the prior
patients perhaps fall into a subcategory of rapidly aggressivemalig-
nant phyllodes tumors. Even in that, there are limited reports and
data on patients like ours. Our patient had thismass of ‘many years’
however, it ‘rapidly’ enlarged in the prior weeks to presentation.
Perhaps there was a malignant transformation at the genetic level
which accelerated the rate of spread of her disease in those prior
weeks. In all likelihood presenting with metastatic disease is likely
a risk factor for local recurrence at the original site.
A question for our patient would have been continued treat-
ment had she not had such aggressive disease. Is there a beneﬁt
of radiation therapy or systemic therapy in malignant phyllodes
tumors? Also, would the patient have been a candidate for future
surgery for her pulmonary metastases? The beneﬁt or role of adju-
vant therapy is not well established. This is secondary to the lack
of randomized trials and rarity of this tumor. Currently there is
no consensus regarding radiotherapy. Most studies have involved
those treated with wide local excision and not necessarily those
treated with mastectomy [28,29]. Belkacemi et al. reported that
radiotherapy was associated with superior local control rate at 10
years, from 59% to 86% for both borderline and malignant phyl-
lodes tumors [30]. Also, in aprospectivemulti-institutional studyof
adjuvant radiotherapy (RT) on46patientswithborderlineormalig-
nant phyllodes tumors treatedwithwide local excision followed by
RT, there were no local recurrences with a median follow up of 56
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Fig. 3. Theupper panel shows themost typical phyllodes sampled (10×), themiddle
panel chondroid differentiation (40×), and the lower panel squamous ‘pearls’ (10×).
months [31]. Two patients with malignant phyllodes tumor died
of metastatic disease. Due to the fact that our patient was treated
with simplemastectomy andhad surgicalmargins at roughly 1mm
adjuvant radiotherapymight havedecreasedher rate of local recur-
rence, however there are no data we found where a patient with
metastatic diseasewas treatedwithRT.Ourpatientwouldhavehad
to have her metastatic disease dealt with likely before the subject
of radiation therapy could have been approached.
Systemic chemotherapy and hormonal therapy is debatable in
phyllodes tumor. To date there is no double blinded, multicen-
ter study on this topic. There was an observational study over a
10 year period with patients treated with doxorubicin plus dacar-
bazine or observation alone after surgical resection [32]. Based on
the limited data available on systemic therapy of soft tissue sar-
coma, adjuvant chemotherapy could possibly be offered to patients
with large (>5 cm), high-risk or recurrent malignant tumors. This
would be better understood through an evaluation of adjuvant and
neo-adjuvant chemotherapy for soft tissue sarcoma which is not
within the scope of this case report. Turalba et al. showed that dox-
orubicin and ifosfamide-based chemotherapies have some efﬁcacy
in women with metastatic phyllodes tumors [33]. Hormonal ther-
apy is not effective in phyllodes tumor. This is despite the presence
of positive hormone receptors. The hormone receptors are com-
ponent of the epithelial aspect of the tumor whereas the stromal
aspect of the tumor is responsible for themetastatic behavior of the
tumor [34]. The receptor from the stromal component expresses
estrogen receptor beta, not alpha as with adenocarcinoma [35,36].
To date, there is no established role for adjuvant chemotherapy or
hormonal therapy in phyllodes tumor. Had our patient presented
earlier and despite limited data, she might have been a candidate
for systemic therapy.
4. Conclusion
In conclusion our patient presented with an aggressive
metastatic form of phyllodes tumor. Based on physical exam alone
the case is extraordinary. Throughphysical examination andbiopsy
data alone, in accordancewithprognostic criteria, shewas at anele-
vated risk for local recurrence and further metastatic disease. Even
with this understanding, it would have been near impossible to
predict such a rapid course of disease progression as she displayed
due to the limitations of our knowledge of this disease. Our case
illustrates the unpredictable nature of this disease in general and
it likely sheds light on a variant of the phyllodes tumor which had
undergone an aggressive transformation.
Conﬂict of interest
No ﬁnancial disclosure.
Funding
N/A.
Consent
Consent obtained from next of kin.
Author contribution
Nathan Roberts- data, writing.
References
[1] J. Muller, Uber den feineren Ban und Die Formen der Krankaften Geschwulste,
about the ban and the ﬁner forms of tumors krankaften Berlin, Germany: G
Reimer (1838).
[2] L. Bernstein, D. Deapen, The descriptive epidemiology of malignant
cystosarcoma phyllodes tumors of the breast, Cancer 71 (1993) 3020–3024.
[3] Azzopardi, Sarcoma in the breast, in: J. Benningron (Ed.), Problems in
Pathology, WB Saunders Co., Philadelphia, 1979, pp. 355–359.
[4] B. Pietruszka, Cystosarcoma phyllodes. a clinicopathological analysis of 42
cases, Cancer 41 (1978) 1974–1983.
[5] S.J. Parker, S.A. Harries, Phyllodes tumors, Postgrad. Med. J. 77 (2001)
428–435.
[6] L. Bernstein, D. Deapen, The descriptive epidemiology of malignant
cystosarcoma phyllodes tumors of the breast, Cancer 71 (1993) 3020–3024.
[7] Barth, Histological features predict local recurrence after breast conserving
therapy of phyllodes tumors, Breast Cancer Res. Treat. 57 (1999) 291–295.
[8] M.A. Guerrero, B.R. Ballard, Malignant phyllodes tumor of the breast: review
of the literature and case report of stromal overgrowth, Surg. Oncol. 12 (2003)
27–37.
[9] M. Reinfuss, J. Mitus, The treatment and prognosis of patients with phyllodes
tumor of the breast: an analysis of 170 cases, Cancer 77 (1996) 910–916.
[10] S. Cheng, Y. Chang, et al., Phyllodes tumor of the breast: the challenge persists,
World J. Surg. 30 (2006) 1212–1221.
[11] O. Macdonald, C. Lee, Malignant phyllodes tumor of the female breast, Cancer
107 (2006) 2127–2133, SEER program.
[12] C. Moffat, S. Pinder, Phyllodes tumors of the breast: a clinicopathological
review of 32 cases, Histopathology 27 (1995) 205–218.
[13] O. Asoglu, M. Ugurlu, Risk Factors for recurrence and death after primary
surgical treatment of malignant phyllodes tumors, Ann. Surg. Oncol. 11
(2004) 1011–1017.
[14] O. Macdonald, C. Lee, Malignant phyllodes tumor of the female breast, Cancer
107 (2006) 2127–2133.
CASE REPORT – OPEN ACCESS
N. Roberts, D.M. Runk / International Journal of Surgery Case Reports 8 (2015) 161–165 165
[15] Y. Belkacemi, G. Bousquet, Phyllodes tumors of the breast, Int. J. Oncol. Biol.
Phys. 70 (2008) 492–500.
[16] M.A. Guerrero, B.R. Ballard, Malignant phyllodes tumor of the breast: review
of the literature and case report of stromal overgrowth, Surg. Oncol. 12 (2003)
27–37.
[17] World Health Organization, Histological typing of breast tumors, Tumori 68
(1982) 181–198.
[18] M. Pietruszka, L. Barnes, Cystosarcoma phyllodes, Cancer 41 (1978)
1974–1983.
[19] H.J. Norris, H.B. Taylor, Relationship of histological features to behavior of
cystosarcoma phyllodes: analysis of 94 cases, Cancer 20 (1967)
2090–2099.
[20] D.B. Rix, S.J. Tredwell, Cystosarcoma phyllodes: clinical-pathological
relationships, Can. J. Surg. 14 (1971) 31–37.
[21] R.M. Ward, H.L. Evans, Cystosarcoma phyllodes: a clinicopathological study of
26 cases, Cancer 58 (1986) 2282–2289.
[22] K. Kario, S. Maeda, et al., Phyllodes tumore of the breast: a clinciopathologic
study of 34 cases, J. Surg. Oncol. 45 (1990) 46–51.
[23] I. Kapiris, M. Nasiri, R. A’Hern, V. Healy, G.P. Gui, Outcome and predictive
factors of local recurrence and distance metastases following primary surgical
treatment of high-grade malignant phyllodes tumors of the breast, Eur. J.
Surg. Oncol. 27 (2001) 723–730.
[24] R.J. Barth, Histological features predict local recurrence after breast
conserving therapy of phyllodes tumors, Breast Cancer Res. Treat. 57 (1999)
291–295.
[25] A. Oktar, M. Mustafa, et al., Risk factors for recurrence and death after primary
surgical treatment of malignant phyllodes tumors, Ann. Surg. Oncol. 11
(2004) 1011–1017.
[26] V. Andrea, C. Bradyl, et al., Clinicopathological features and long-term
outcomes of 293 phyllodes tumors of the breast, Ann. Surg. Oncol. 14 (2007)
2961–2970.
[27] B. Geisler, et al., Phyllodes tumors of the breast: a review of 32 cases, Am.
Surg. 66 (2000) 4.
[28] R.E. Hawkins, J.B. Schoﬁeld, et al., The clinical and histologic criteria that
predict metastases from cystosarcoma phyllodes, Cancer 69 (1992) 141.
[29] J. Fajdic, N. Gotovac, et al., Phyllodes tumors of the breast diagnostic and
therapeutic dilemmas, Onko 30 (2007) 113.
[30] Y. Belkacemi, G. Bousquet, et al., Phyllodes tumor of the breast, Int. J. Radiat.
Oncol. Biol. Phys. 70 (2008) 492.
[31] R.J. Barth, W.A. Wells, et al., A prospective, multi-institutional study of
adjuvant radiotherapy after resection of malignant phyllodes tumors, Ann.
Surg. Oncol. 16 (2009) 2288.
[32] J. Morales-Vasquez, et al., Adjuvant chemotherapy with doxorubicin and
dacarbazine has no effect in recurrence-free survival of malignant phyllodes
of the breast, breast Journal 13 (2007) 551.
[33] C.I. Turalba, A.M. el-Mahdi, Fatal metastatic cystosarcoma phylloides in an
adolescent female: case report and review of treatment approaches, J. Surg.
Oncol. 33 (1986) 176–181.
[34] M.L. Telli, K.C. Horst, Phyllodes tumors of the breast: natural history,
diagnosis and treatment, J. Natl. Compr. Cancer Network 5 (2007) 324.
[35] A. Sapino, M. Bosco, et al., Estrogen receptor-beta is expressed in stromal cells
of ﬁbroadenoma and phyllodes tumors of the breast, Mod. Pathol. 19 (2006)
599.
[36] G.M. Tse, C.S. Lee, et al., Hormonal receptors expression in epithelial cells of
mammary phyllodes tumors correlates with pathologic grade of the tumor: a
multicenter study of 143 cases, Am. J. Clin. Pathol. 118 (2002) 522.
Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which
permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are
credited.
